Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series.
Dooley AJ. et al, (2014), Ther Adv Med Oncol, 6, 262 - 266
Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia.
Harrison CN. et al, (2014), Br J Haematol, 167, 421 - 423
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
Reilly JT. et al, (2014), Br J Haematol, 167, 418 - 420
Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.
Gao S. et al, (2014), Cancer Res, 74, 5866 - 5877
Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation.
Bensaad K. et al, (2014), Cell Rep, 9, 349 - 365
A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma
Middleton M. et al, (2014), CANCER RESEARCH, 74
Baseline 18F-FDG PET-CT factors associated with progression to metastatic disease during neoadjuvant therapy for esophageal cancer
Findlay JM. et al, (2014), EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 41, S233 - S233
OCULAR TOXICITIES OBSERVED WITH MEK INHIBITOR RO4987655 (CH4987655) IN A SINGLE AGENT PHASE I STUDY WITH EXTENSION IN PATIENTS WITH ADVANCED SOLID TUMORS
Leijen S. et al, (2014), BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 78, 769 - 769
The added value of 18F-FDG PET-CT in restaging esophageal cancer after neoadjuvant therapy
Findlay JM. et al, (2014), EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 41, S524 - S524
Translational Modelling of Vemurafenib, Selumetinib and Docetaxel in Metastatic Melanoma with Virtual Tumour Clinical
Brightman F. et al, (2014), JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 41, S64 - S64
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
Zimmer L. et al, (2014), Clin Cancer Res, 20, 4251 - 4261
Individual risk modelling for esophagectomy: a systematic review.
Findlay JM. et al, (2014), J Gastrointest Surg, 18, 1532 - 1542
Ipilimumab associated colitis: a modern mimic of Inflammatory Bowel Disease (IBD)
Tripathi M. et al, (2014), VIRCHOWS ARCHIV, 465, S235 - S236
Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.
Eyre TA. et al, (2014), Br J Haematol, 166, 336 - 351
Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
Rule S. et al, (2014), J Med Econ, 17, 459 - 468
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo
Woll PS. et al, (2014), Cancer Cell, 25, 794 - 808
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.
Woll PS. et al, (2014), Cancer Cell, 25, 794 - 808
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN A SINGLE UK CENTRE: COMPARISON WITH PRE-TKI ERA AND EVALUATION OF 2013 ELN GUIDELINES
Khan D. et al, (2014), HAEMATOLOGICA, 99, 341 - 341
A NATIONAL EXPERIENCE OF THE USE OF PONATINIB IN PATIENTS MULTIPLE TYROSINE KINASE INHIBITORS CONFIRMS EFFICACY IN A HEAVILY PRE-TREATED COHORT OF PATIENTS WITH PH plus LEUKAEMIAS
Milojkovic D. et al, (2014), HAEMATOLOGICA, 99, 335 - 335